IP Receptor Agonist Heterocyclic Compounds

Rebecca Butler; Catherine Leblanc; Stephen Carl McKeown; Steven John Charlton

IP Receptor Agonist Heterocyclic Compounds

Rebecca Butler (Inventor), Catherine Leblanc (Inventor), Stephen Carl McKeown (Inventor), Steven John Charlton (Inventor)

Research output: Patent

Abstract

The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed.

Original language	English
Patent number	US2015376183A1
IPC	A61K3 1/4375,C07D47 1/04
Priority date	11/02/14
Filing date	11/02/14
Publication status	Published - 31 Dec 2015
Externally published	Yes

Cite this

@misc{dfcb948acbb74b05b269478bc193f5ba,

title = "IP Receptor Agonist Heterocyclic Compounds",

abstract = "The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed.",

author = "Rebecca Butler and Catherine Leblanc and McKeown, \{Stephen Carl\} and Charlton, \{Steven John\}",

year = "2015",

month = dec,

day = "31",

language = "English",

type = "Patent",

note = "US2015376183A1; A61K3 1/4375,C07D47 1/04",

}

TY - PAT

T1 - IP Receptor Agonist Heterocyclic Compounds

AU - Butler, Rebecca

AU - Leblanc, Catherine

AU - McKeown, Stephen Carl

AU - Charlton, Steven John

PY - 2015/12/31

Y1 - 2015/12/31

N2 - The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed.

AB - The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed.

UR - https://worldwide.espacenet.com/patent/search/family/050193553/publication/US2015376183A1?q=US2015376183

UR - https://patentimages.storage.googleapis.com/8c/b8/38/2d36eb4ba806f5/US20150376183A1.pdf

M3 - Patent

M1 - US2015376183A1

Y2 - 2014/02/11

ER -

IP Receptor Agonist Heterocyclic Compounds

Abstract

Other files and links

Fingerprint

Cite this